Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4331-4339

  Dang, Qun ^a   Kasibhatla, Srinivas Rao ^a,b   Jiang, Tao ^a,c   Fan, Kevin ^a,c   Liu, Yan ^a,d   Taplin, Frank ^a   Schulz, William ^a   Cashion, Daniel K ^a   Reddy, K Raja ^a   Van Poelje, Paul D ^a   Fujitaki, James M ^a   Potter, Scott C ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

^b JUBILANT BIOSYS LTD   (India)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; AMINO ACID DERIVATIVE; DIAMIDE; FRUCTOSE 1,6 BISPHOSPHATASE INHIBITOR; FRUCTOSE BISPHOSPHATASE; GLUCOSE; MB 05032; MB 06322; PHOSPHONIC ACID DERIVATIVE; PRODRUG; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; MOLECULAR WEIGHT; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; BLOOD GLUCOSE; DRUG STABILITY; ENZYME INHIBITORS; FRUCTOSE-BISPHOSPHATASE; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHONIC ACIDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 47749099269     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8001235     Document Type: Article

References (27)

1. Erion, M. D.; van Poelje, P. D.; Dang, Q.; Kasibhatla, S. R.; Potter, S. C.; Reddy, M. R.; Reddy, K. R.; Jiang, T.; Lipscomb, W. N. MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7970-7975.
2. Erion, M. D.; Dang, Q.; Reddy, M. R.; Kasibhatla, S. R.; Huang, J.; Lipscomb, W. N.; van Poelje, P. D. Structure-guided design of AMP mimics that inhibit fructose 1,6-bisphosphatase with high affinity and specificity. J. Am. Chem. Soc. 2007, 129, 15480-15490.
3. Dang, Q.; Kasibhatla, S. R.; Reddy, K. R.; Jiang, T.; Reddy, M. R.; Potter, S. C.; Fujitaki, J. M.; van Poelje, P. D.; Huang, J.; Lipscomb, W. N.; Erion, M. D. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J. Am. Chem. Soc. 2007, 129, 15491-15502.
4. Dang, Q. Organophosphonic acids as drug candidates. Expert Opin. Ther. Pat. 2006, 16, 343-348.
5. Krise, J. P.; Stella, V. J. Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Delivery Rev. 1996, 19, 287-310.
6. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med. Chem. 2008, 51, 2328-2345.
7. Farquhar, D.; Srivastva, D. N.; Kattesch, N. J.; Saunders, P. P. Biologically reversible phosphate-protective groups. J. Pharm. Sci. 1983, 72, 324-325.
8. Mitchell, A. G.; Thompson, W.; Nicholls, D.; Irwin, W. J.; Freeman, S. Prodrugs of phosphonoformate: the effect of para-substituents on the products, kinetics and mechanims of hydrolysis of dibenzyl methoxycarbonylphosphonate. J Chem. Soc., Perkin Trans. 2 1992, 1145.
9. Dang, Q.; Liu, Y.; Rydzewski, R. M.; Brown, B. S.; Robinson, E.; van Poelje, P. D.; Colby, T. J.; Erion, M. D. Bis [(para-methoxy)benzyl] phosphonate prodrugs with improved stability and enhanced cell penetration. Bioorg. Med. Chem. Lett. 2007, 15, 3412-3416.
10. Lefebvre, I.; Perigaud, C.; Pompon, A.; Aubertin, A. M.; Girardet, J. L.; Kirn, A.; Gosselin, G.; Imbach, J. L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′- dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
11. McGuigan, C.; Pathirana, R. N.; Mahmood, N.; Devine, K. G.; Hay, A. J. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992, 17, 311-321.
12. McGuigan, C.; Nickson, C.; Petrik, J.; Karpas, A. Phosphate derivatives of AZT display enhanced selectivity of action against HIV 1 by comparison to the parent nucleoside. FEBS Lett. 1992, 310, 171-174.
13. Erion, M. D.; Reddy, K. R.; Boyer, S. H.; Matelich, M. C.; Gomez-Galeno, J.; Lemus, R. H.; Ugarkar, B. G.; Colby, T. J.; Schanzer, J.; Van Poelje, P. D. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 2004, 126, 5154-5163.
14. Lee, W. A.; He, G. X.; Eisenberg, E.; Cihlar, T.; Swaminathan, S.; Mulato, A.; Cundy, K. C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 2005, 49, 1898-1906.
15. Jones, B. C. N. M.; McGuigan, C.; O'Connor, T. J.; Jeffries, D. J.; Kinchington, D. Synthesis and anti-HIV activity of some novel phosphoradiamidate derivatives of 3′-azido-3′-deoxythymidine (AZT). Antivir. Chem. Chemother. 1991, 2, 35-39.
16. Serafinowska, H. T.; Ashton, R. J.; Bailey, S.; Harnden, M. R.; Jackson, S. M.; Sutton, D. Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine. J. Med. Chem. 1995, 38, 1372-1379.
17. Keith, K. A.; Hitchcock, M. J.; Lee, W. A.; Holy, A.; Kern, E. R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 2003, 47, 2193-2198.
18. Mukaiyama, T.; Hashimoto, M. Phosphorylation of alcohols and phosphates by oxidation-reduction condensation. Bull. Chem. Soc. Jpn. 1971, 44, 196-199.
19. Mukaiyama, T.; Hashimoto, M. Phosphorylation by oxidation-reduction condensation: preparation and reaction of S-(2-pyridyl)phosphorothioates. Tetrahedron Lett. 1971, 26, 2425-2428.
20. McGuigan, C.; Harris, S. A.; Daluge, S. M.; Gudmundsson, K. S.; McLean, E. W.; Burnette, T. C.; Marr, H.; Hazen, R.; Condreay, L. D.; Johnson, L.; De Clercq, E.; Balzarini, J. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J. Med. Chem. 2005, 48, 3504-3515.
21. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3.
22. van de Waterbeemd, H.; Jones, B. C. Predicting oral absorption and bioavailability. Prog. Med. Chem. 2003, 41, 1-59.
23. Gomez-Orellana, I. Strategies to improve oral drug bioavailability. Expert Opin. Drug Delivery 2005, 2, 419-433.
24. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol. 2006, 2, 591-608.
25. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
26. Stebbins, J. W.; Haughey, M. P.; Wu, R.; Hou, J.; Fujitaki, J. M.; van Poelje, P. D.; Linemeyer, D. L. Manuscript submitted for publication.
27. Unpublished results.